Geoffrey Porges
Stock Analyst at SVB Leerink
(1.35)
# 3,462
Out of 4,941 analysts
122
Total ratings
42.86%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $24.64 | +127.27% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $9.69 | +932.52% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $556.48 | +52.75% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $64.04 | -25.05% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $284.93 | -24.19% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $198.64 | -32.04% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.56 | -4.84% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $120.08 | -37.54% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $48.05 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $11.86 | -15.68% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $9.03 | +8,205.65% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $388.08 | -54.91% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $23.91 | +251.32% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $38.22 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $8.46 | +621.04% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $128.61 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $24.64
Upside: +127.27%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $9.69
Upside: +932.52%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $556.48
Upside: +52.75%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $64.04
Upside: -25.05%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $284.93
Upside: -24.19%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $198.64
Upside: -32.04%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.56
Upside: -4.84%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $120.08
Upside: -37.54%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $48.05
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $11.86
Upside: -15.68%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $9.03
Upside: +8,205.65%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $388.08
Upside: -54.91%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $23.91
Upside: +251.32%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $38.22
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $8.46
Upside: +621.04%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $128.61
Upside: -